Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients

Area of Science:

• Hepatology and Infectious Diseases
• Public Health and Correctional Medicine

Background:

• Rising end-stage liver disease necessitates hepatitis C (HCV) treatment for human immunodeficiency virus (HIV)-coinfected patients.
• Significant barriers, including substance abuse and lifestyle factors, limit HCV treatment in HIV-positive individuals within the community.
• Correctional facilities offer a structured environment conducive to managing complex medical therapies.

Purpose of the Study:

• To evaluate the efficacy and feasibility of providing HCV treatment to HIV-infected inmates.
• To assess the potential of the prison system to overcome common barriers to HCV treatment.

Main Methods:

• Utilized the structured prison environment to administer complex HCV therapies alongside substance abuse programs.
• Implemented close monitoring of patient adherence and adverse effects during treatment.
• Focused on HIV-seropositive individuals incarcerated within the system.

Main Results:

• The prison setting facilitates the delivery of comprehensive HCV treatment to HIV-coinfected patients.
• Close monitoring in correctional facilities aids in managing adherence and side effects effectively.
• This strategy efficiently reaches underserved minority populations with limited community healthcare access.

Conclusions:

• Incarceration provides a viable and efficient setting for treating HCV in HIV-positive individuals.
• Correctional-based HCV treatment programs can significantly improve health outcomes for a high-risk, underserved population.
• This model demonstrates a successful strategy for addressing health disparities in infectious disease management.